IRVINE, Calif.--(BUSINESS WIRE)--Cortex Pharmaceuticals, Inc. (OTCBB:CORX) announced the issuance by The United States Patent and Trademark Office (USPTO) of two key patents that protect the next generation of AMPAKINE® compounds. Specifically, these new AMPAKINE patents cover a series of compounds including the lead preclinical compounds, CX2007 and CX2076. These compounds exhibit a long duration of action and excellent pharmacokinetic properties, making them ideal for a once-a-day therapy.
